Catena is a UC Berkeley spinout building a site-selective enzymatic conjugation platform (CysTyr/Catenase) that attaches multiple, structurally distinct payloads to a single antibody — the technical constraint that has held next-generation ADCs to single-payload designs. The wedge is a novel C–Y bond formed enzymatically between native tyrosine and cysteine residues, giving stability, scalability, and combinatorial flexibility that legacy linker chemistries (maleimide, click) can't match; pre-clinical MPC data presented at SABCS 2023 and AACR 2024 show tumor kill against HER2+ lines that the founder describes as beating DS8201a / Enhertu in vitro Internal.
As of the 2024-12-11 note, Marco reserved $200K for SH inside a $5M+ Seed II on a $25M SAFE cap — same terms as the prior round (flat), with Civilization Ventures verbally in for ~$4M pending signatures, $250K from Cal Innovation Fund, and ~$250K from angels; the round was on track to close before year-end and did (closed 2024-12-30, per Deal record). Company has a National Cancer Institute collaboration and three top-10 pharma partnerships in progress per the 2024-11-22 call, and the board opened the SAFE specifically to fund cell banking ahead of the holidays (2024-11-16 email). SH took $200K via Fund I alongside LongeVC, Civilization Ventures, Social Impact Capital, and Y Combinator.
Analyst ranges vary but converge on ADCs as one of the fastest-growing oncology modalities of the decade — Pfizer's $43B acquisition of Seagen (closed Dec 2023) (Web) and AbbVie's ~$10B ImmunoGen deal (Web) are the clearest signal that big pharma is buying the category. The current wave of approved ADCs is single-payload; a validated multi-payload platform sits directly in the path of the next wave.
| Player | Positioning | Funding / Stage | Edge vs. them |
|---|---|---|---|
| Catena Biosciences | Enzymatic CysTyr / Catenase platform for multi-payload ADCs (MPCs); pre-clinical | Seed II, $25M SAFE cap | — |
| Ambrx (acq. J&J) | Site-specific conjugation via unnatural amino acids; commercial-stage partnerships | Acquired by J&J for ~$2B, closed Mar 2024 Web | Catena uses only native amino acids + enzymatic chemistry; targets multi-payload rather than site-specific single payload |
| Sutro Biopharma | Cell-free XpressCF platform for site-specific ADCs Web | Public, clinical-stage | Enzymatic vs. cell-free; simpler manufacturing path via CDMOs |
| Mersana Therapeutics | Dolaflexin / Immunosynthen ADC platforms Web | Public, clinical-stage | Different linker chemistry; Catena claims broader payload flexibility |
| Seagen (Pfizer) / Enhertu (Daiichi–AZ) | Approved single-payload ADCs (Enhertu / T-DXd is HER2+ standard of care) | Commercial; Seagen sold to Pfizer for $43B in Dec 2023 Web | Catena's MPCs benchmarked in vitro vs. DS8201a on HER2+ lines per founderInternal |
Moat: IP moat around the C–Y bond formation, with claims awarded in Japan for the linking process per the 2024-11-22 note; the enzymatic approach on native amino acids is defensible chemistry that competitors would need to design around.
Recent ADC M&A comps set the ceiling: Pfizer–Seagen at $43B (Web), AbbVie–ImmunoGen at ~$10B (Web), and J&J–Ambrx at ~$2B. Likely acquirers: Pfizer, AstraZeneca/Daiichi Sankyo, Merck, Roche, AbbVie, BMS — every top-10 oncology franchise wants a next-gen ADC platform. Realistic exit path is platform validation via a signed pharma option + preclinical/Phase 1 handoff, then strategic M&A on the same pattern; $25M entry against even a mid-hundreds-of-millions platform deal is a 10–20x, and against the Ambrx-scale comp is 40x+.
Short update from Marco: SH slot confirmed at $200K, CV verbally $4M pending signatures, plus Cal Fund and angel commitments — full $5M targeted to close by year-end on a SAFE.
RAW NOTES:
He is excited to have us involved and will reserve $200K for us.
Sounds like CV has verbally said $4M and they are pending signatures.
Also has $250K from Cal Fund and another $250K in hard commitments from individuals.
Will likely close on the full $5M before the end of the year. Will still do it all on a SAFE.
Full diligence call. Team, platform mechanics, competitive positioning vs. Enhertu / Trodelvy, partnership landscape (NCI + three top-10 pharma), and round dynamics ($5M Seed II on $25M SAFE cap, LongeVC lead, ~5 months runway to Q2). Only pause noted was that the round is flat.
INTRO AND INTEL SOURCE: Cold Inbound. DEAL STATUS: In Conversation.
NEXT STEPS: Reach out to Freeflow team from Karma deal and to Civilization Ventures. Send DD form / get data room access from them.
SUMMARY OF CALL: Depending on calls with Freeflow and Shahram — consider $100K–$250K. Definitely one we want to do. Only slight pause is the fact that it's being done flat — get insights from insiders.
Team & Founders: Marco — PO and PhD at Berkeley with Francis and Doudna. Saurabh — CBO, big-pharma background in strategy and oncology. Rick Kendall — CSO, Amgen for 17 years and head of oncology division. 7 scientists in the lab. Jennifer advises and makes introductions but this company is not CRISPR. Matt Francis is more involved and expert on bio-conjugation — in the lab with them a few hours a week.
Company & Insight: platform technology that enables novel conjugate therapeutics; next-gen ADCs with capacity for multiple payloads. "We don't have the tools we need to build the types of molecules we want." Current ADCs are limited to single payloads or type of drugs — especially for cancer tumors. Insight: platform can combine multiple payloads without limitations on complexity and size. Awarded claims in Japan for their linking process / strong IP moat and claim set — ability to create a bond between two target amino acids (first tech that can do this for small molecules but also larger molecules).
Market & Competitors: Enhertu is best drug out there for tumor elimination right now. Trodelvy for triple-negative breast cancer. Their early data on MPCs are showing significantly more tumor elimination compared to both.
Traction: Closed a deal with National Cancer Institute (NCI) building ADCs for them. NCI could pay for their Phase 1 clinical trial. Already working with three top-10 pharma partners: proteins and gene-therapy space primarily — planning to bring on these partners in more meaningful ways.
Round Dynamics & Financials: Previous financing ~$8M raised. LongeVC was lead; Civilization Ventures, Freeflow Ventures, Y Combinator, Social Impact Capital. $5M Seed 2 raise — would like to get a couple million before end of year but five in total. Few internals to re-up. Talking to folks from Jennifer. Soft commitments. Same terms from last $25M Post SAFE. Runway to Q2 at the moment.
ROUND TERMS / POST-MONEY VALUATION: $5M Seed 2 on $25M SAFE Cap.
Marco emails that after significant cajoling the board opened up the SAFE to a small group so Catena can launch cell banking before the holidays; new data deck attached.
Update from Marco Lobba re: SAFE.
Hey team, hope all is well! After significant cajoling I've managed to get the board to open up on letting a few folks in on the SAFE so we can launch cell banking before the holidays. Would love to connect at chat logistics if you're open to it! New data deck attached. — Marco